- Conditions
- Intracranial Tumors, Glioblastoma, Melanoma
- Interventions
- PBR PET, Cancer Immunotherapy, Radiation and chemotherapy
- Other · Biological · Radiation
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 1,724
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Malignant Melanoma
- Interventions
- HyperAcute-Melanoma Vaccine
- Biological
- Lead sponsor
- NewLink Genetics Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Cervical Intraepithelial Neoplasia
- Interventions
- ADXS11-001 (Lm-LLO-E7), Placebo Control
- Biological · Drug
- Lead sponsor
- Advaxis, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 15
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 10 more
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
- Interventions
- Galinpepimut-S, GM-CSF, Montanide
- Biological · Other
- Lead sponsor
- Sellas Life Sciences Group
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Covid19, SARS-CoV2 Infection
- Interventions
- Study-provided Moderna mRNA-1273 COVID-19 vaccine, Community-provided Moderna mRNA-1273 COVID-19 Vaccine, Community-Provided Pfizer-BioNTech BNT162b2 COVID-19 Vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 6
- States / cities
- Los Angeles, California • San Diego, California • Chicago, Illinois + 3 more
- Conditions
- Dermatitis Atopic
- Interventions
- Amlitelimab, Placebo, Tdap vaccine, PPS vaccine
- Drug · Biological
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Anaheim, California + 40 more
- Conditions
- ASC-US, ASC-H, LSIL
- Interventions
- PVX-2, Placebo
- Biological · Other
- Lead sponsor
- PapiVax Biotech, Inc.
- Other
- Eligibility
- 25 Years to 70 Years · Female only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 6
- States / cities
- Port Saint Lucie, Florida • Newark, New Jersey • Fairfield, Ohio + 3 more
- Conditions
- Central Nervous System Neoplasm
- Interventions
- trivalent influenza vaccine, laboratory biomarker analysis
- Biological · Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Influenza, Human, Infections, Respiratory Tract Infections, Virus Diseases, Infection Viral
- Interventions
- aH5N8c on Day 1, aH5N6c on Day 1, aH5N8c on Day 22, aH5N6c on Day 22, aH5N8c on Day 202
- Biological
- Lead sponsor
- Seqirus
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 480 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 9
- States / cities
- Cullman, Alabama • Lilburn, Georgia • Norcross, Georgia + 6 more
- Conditions
- Stage IV Melanoma, Recurrent Melanoma
- Interventions
- gp100 antigen, interleukin-2
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 16 Years and older
- Timeline
- 1998 – 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Healthy Volunteers, Norovirus
- Interventions
- NoV Vaccine
- Biological
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 528 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2021
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Fountain Hills, Arizona • Littleton, Colorado + 6 more
- Conditions
- Smoke Exposure, Influenza
- Interventions
- LAIV nasal vaccine is chosen as a model viral infection, Wood smoke, Placebo for LAIV nasal vaccine is chosen as a model viral infection, Placebo for Wood Smoke (clean Air Exposure)
- Biological · Other
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Health Knowledge, Attitudes, Practice, Vaccine-Preventable Diseases, Intention, Adherence, Patient
- Interventions
- Culturally Tailored Multimedia Psychoeducational HPV Intervention, General HPV Multimedia Psychoeducational Control Group
- Behavioral
- Lead sponsor
- University of Texas, El Paso
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- El Paso, Texas
- Conditions
- COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia, Lymphoma, Plasma Cell Myeloma
- Interventions
- COVID-19 Vaccine, Diagnostic Laboratory Biomarker Analysis, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1
- Biological · Other
- Lead sponsor
- GeoVax, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 6
- States / cities
- Duarte, California • Baltimore, Maryland • Worcester, Massachusetts + 3 more
- Conditions
- Metastatic Renal Cell Carcinoma
- Interventions
- DC vaccine, Bevacizumab, IL-2, IFN
- Biological · Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Recurrent Glioblastoma
- Interventions
- Dendritic Cell Tumor Cell Lysate Vaccine, Pembrolizumab, Placebo Administration, Poly ICLC
- Biological · Other · Drug
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Medication Adherence, Substance Abuse, Intravenous, Risk Behavior, Hepatitis A, Hepatitis B, Hepatitis C
- Interventions
- Hepatitis A & B vaccine, Outreach, AIC, SEP
- Biological · Behavioral
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 14 Years to 29 Years
- Enrollment
- 546 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Pancreatic Cancer
- Interventions
- Cyclophosphamide, GVAX Pancreatic Cancer Vaccine, Pembrolizumab, SBRT
- Drug · Radiation
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Melanoma (Skin)
- Interventions
- aldesleukin, fowlpox virus vaccine vector, gp100 antigen
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1996
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Kidney Cancer
- Interventions
- human prostate-specific membrane antigen plasmid DNA vaccine, mouse prostate-specific membrane antigen plasmid DNA vaccine
- Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Squamous Cell Carcinoma of the Oral Cavity
- Interventions
- GL-0817, Hiltonol, Sargramostim, cyclophosphamide, Placebo
- Drug
- Lead sponsor
- Gliknik Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Decision-Making, Patient Care, Treatment Decisions
- Interventions
- Influenza vaccine, Placebo
- Biological · Other
- Lead sponsor
- University of Arkansas, Fayetteville
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 3
- States / cities
- Fayetteville, Arkansas • Albuquerque, New Mexico • Roanoke, Virginia
- Conditions
- High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Recurrent Medulloblastoma
- Interventions
- PEP-CMV, Temozolomide, Tetanus Diphtheria Vaccine
- Biological · Drug
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 3 Years to 39 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 13
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • Miami, Florida + 10 more
- Conditions
- Newly Diagnosed Pediatric Pontine Glioma, Newly Diagnosed Pediatric High Grade Glioma, Recurrent Pediatric High Grade Glioma, Recurrent Pediatric Low Grade Glioma
- Interventions
- HLA-A2 restricted glioma antigen peptides vaccine, Poly-ICLC
- Biological
- Lead sponsor
- James Felker
- Other
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2024
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania